Dongzhou Jeffery Liu

top of page

From Germany: Most ADCs use microtubule inhibitors or DNA-damaging agents as their payload. Heidelberg Pharma believes a greater diversity is needed and has a unique amanitin payload for its programs

CEO Dongzhou Jeffery Liu describes the science behind amanitin (it is based on natural poisons, which occur in the death cap mushroom) and discusses Heidelberg Pharma's lead program, a BCMA antibody-drug conjugate, and earlier stage ones targeting CD37 and PSMA. Plus, partnerships with Takeda and Huadong Medicine.

Company News

2 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

From Germany: Most ADCs use microtubule inhibitors or DNA-damaging agents as their payload. Heidelberg Pharma believes a greater diversity is needed and has a unique amanitin payload for its programs

Follow BiotechTV

Sponsors

Sponsor Spotlight